Minimum information about a bioactive entity (MIABE) S Orchard, B Al-Lazikani, S Bryant, D Clark, E Calder, I Dix, O Engkvist, ... Nature reviews Drug discovery 10 (9), 661-669, 2011 | 105 | 2011 |
Collaborative Computational Technologies for Biomedical Research C Waller, R Durvasula, N Lynch Wiley, 2011 | 43* | 2011 |
Empowering industrial research with shared biomedical vocabularies L Harland, C Larminie, SA Sansone, S Popa, MS Marshall, ... Drug discovery today 16 (21-22), 940-947, 2011 | 25 | 2011 |
Best practices for artificial intelligence in life sciences research VA Makarov, T Stouch, B Allgood, CD Willis, N Lynch Drug Discovery Today 26 (5), 1107-1110, 2021 | 20 | 2021 |
Sequence squeeze: an open contest for sequence compression RCG Holland, N Lynch GigaScience 2 (1), 2047-217X-2-5, 2013 | 13 | 2013 |
The Next Big Developments–The Lab of the Future R Shute, N Lynch Digital Transformation of the Laboratory: A Practical Guide to the Connected …, 2021 | 1 | 2021 |
Software system rationalisation: How to get better outcomes through stronger user engagement R Shute, N Lynch arXiv preprint arXiv:2210.00236, 2022 | | 2022 |
The Open PHACTS Discovery Platform from a network biology perspective C Evelo, EL Willighagen, N Lynch, B Williams-Jones, A Loizou, ... Network Biology SIG 2016: ISMB 2016 SIG, 2016 | | 2016 |
Semantic-Web Access to Patent Annotations. A Gaulton, L Harland, M Davies, G Papadatos, A Loizou, N Dedman, ... SWAT4LS, 212-213, 2015 | | 2015 |
Shouldn't enantiomeric purity be included in the'minimum information about a bioactive entity? Response from the MIABE group S Orchard, B Al-Lazikani, S Bryant, D Clark, E Calder, I Dix, O Engkvist, ... Nature Reviews Drug Discovery 11 (9), 730-730, 2012 | | 2012 |
Best Practices for Artificial Intelligence in Life Sciences Research T Stouch, B Allgood, C Willis, N Lynch | | |
Response to R Ammann, J Gosper, N Lynch, K Riebs, A Turner | | |
Response to: Entity Differentiation Service Request for Information R Ammann, J Gosper, N Lynch, K Riebs, A Turner | | |